Drug intelligence / Profile preview

isotretinoin + vorinostat

Development stage: Unknown
Lead developer: National Cancer Institute
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of isotretinoin (cis-13-retinoic acid), a retinoid, and vorinostat, a histone deacetylase (HDAC) inhibitor. Preclinical studies demonstrated that vorinostat combined with retinoids produces additive antitumor effects in neuroblastoma. The combination works through complementary mechanisms, with vorinostat inhibiting histone deacetylases, leading to increased histone acetylation and altered gene expression, while isotretinoin acts through retinoid receptors to influence cell differentiation and growth.

Brand names: ZolinzaAccutaneClaravisSotret
Other names: suberoylanilide hydroxamic acidisotretinoin

Targets

HDAC (HDAC family)RARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on isotretinoin + vorinostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isotretinoin + vorinostat.

Explore the full profile